Working… Menu

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01524991
Recruitment Status : Completed
First Posted : February 2, 2012
Last Update Posted : October 15, 2019
Bristol-Myers Squibb
Information provided by (Responsible Party):
Hoosier Cancer Research Network

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 15, 2017
Actual Study Completion Date : December 31, 2018
Galsky MD, Hahn NM, Albany C, Fleming MT, Starodub A, Twardowski P, Hauke RJ, Sonpavde G, Merad M, Gnjatic S, Bhardwaj N, Chippada-Venkata U, Oh WK, Kim-Schulze S. Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC). J Clin Oncol 33:5s, 2015 (suppl; abstr 4586)

Publications automatically indexed to this study by Identifier (NCT Number):